Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

BACKGROUND: We evaluated the efficacy of carboplatin, irinotecan and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial. METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reardon, David A., Desjardins, Annick, Peters, Katherine B., Vredenburgh, James J., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Coan, April, Threatt, Stevie, Friedman, Allan H., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3158844/
https://ncbi.nlm.nih.gov/pubmed/21590689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26188
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados